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PCR revealed the presence of equine herpesvirus 5 (EHV-5) DNA in lung tissue of one horse whereas
in two other horses, asinine herpes virus 5 (AHV-5) was detected. EMPF should be considered as a
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This case series describes three cases of equine multi-
nodular pulmonary fibrosis (EMPF) diagnosed at the 
Clinic for Equine Internal Medicine at the University 
of  Zurich between 2012 and 2017. Current information 
on etiology and treatment options are presented. Two 
horses showed mild signs of chronic lower respiratory 
tract disease and one horse was presented with acute 
signs of disease including recurrent fever spikes and 
tachypnea. Diagnosis was achieved by physical exami-
nation, radiographic findings, and PCR testing for 
equine herpesviruses (EHV) of bronchoalveolar lavage 
(BAL) fluid or lung tissue obtained by biopsy. All hors-
es were euthanized due to continuing deterioration after 
attempted treatment. Post mortem histological exami-
nation of lung tissue showed severe multifocal diffuse 
to confluent fibrosis in two cases and in another horse 
a discrete nodular fibrosis pattern. Panherpes nested 
PCR revealed the presence of equine herpesvirus 5 
(EHV-5) DNA in lung tissue of one horse whereas in 
two other horses, asinine herpes virus 5 (AHV-5) was 
detected. EMPF should be considered as a differential 
diagnosis in horses with acute and chronic respiratory 
disease, including horses non-responsive to treatment 
for equine asthma. 
Keywords: asinine herpes virus 5; equine herpesvirus 5; 
horse; interstitial pneumonia;  pulmonary fibrosis
Die Rolle von verschiedenen Gamma-
herpesviren in einer Fallserie von 
Equiner multinodulärer pulmonalen 
Fibrose
Diese Fallserie beschreibt drei Fälle von Equiner multi-
nodulärer pulmonaler Fibrose (EMPF), die zwischen 
2012 und 2017 an der Klinik für Innere Medizin für 
Pferde der Universität Zürich diagnostiziert wurden. Der 
aktuelle Wissensstand zur Ätiologie und Behandlungs-
möglichkeiten werden vorgestellt. Zwei Pferde zeigten 
leichte Anzeichen einer chronischen Erkrankung der 
unteren Atemwege. Ein Pferd hatte Anzeichen einer 
akuten Erkrankung mit Fieberschüben und Tachypnoe. 
Die Diagnose konnte durch die klinische Untersuchung, 
radiologische Befunde und die Untersuchung der bron-
choalveolären Lavage (BAL) oder Lungenbiopsie auf 
Equine Herpesviren (EHV) mittels Polymerase Ketten-
reaktion (PCR) bestätigt werden. Aufgrund der klini-
schen Verschlechterung mussten alle Pferde euthanasiert 
werden. Pathohistologische Untersuchungen des Lun-
gengewebes zeigte eine schwere multifokale diffuse bis 
konfluente Fibrose in zwei Fällen und ein diskretes 
 Muster von knotiger Fibrose in einem Fall. Mittels 
 Panherpes PCR (Nested PCR) konnte bei einem Pferd 
DNA von Equinem Herpesvirus 5 (EHV-5) und bei zwei 
Pferden Asinin-Herpesvirus 5 (AHV-5) in der Lunge 
nachgewiesen werden. Bei Pferden mit akuten und chro-
nischen Atemwegserkrankungen, oder Pferden, die nicht 
auf die Behandlung von Asthma ansprechen, sollte 
EMPF als Differenzialdiagnose in Betracht gezogen 
werden. 
Schlüsselwörter: Asinin-Herpesvirus 5; Equines Herpes-
virus 5; Pferd; interstitielle Pneumonie; Lungenfibrose
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Introduction
Equine multinodular pulmonary fibrosis (EMPF) is 
a rare interstitial lung disease affecting horses at all 
ages.1-16 The etiology is not fully elucidated, but gamma 
herpes viruses likely play a major role. Gamma herpes-
viruses have been shown to induce pulmonary fibrosis 
in experimental murine γ-herpesvirus 68 (MHV68) 
models (officially murid herpesvirus type 4 (MuHV-4)), 
as well as in humans with idiopathic pulmonary fibrosis 
(Epstein-Barr Virus (EBV) infection).17-19 Experimental 
infection with equine herpes virus 5 (EHV-5) has also 
been shown to induce pulmonary fibrosis in horses in 
vitro and in vivo.20 The first published case series from 
2007 described coinfection with EHV-2 in approximate-
ly 30% of the cases.12 Co-infection with EHV-2 has since 
been described in approximately 20% of cases (Table 1). 
EHV-2 and EHV-5 belong to the family of gamma her-
pesviruses, which also include equine herpesvirus 7 
(EHV-7, also referred to as asinine herpesvirus 2 
(AHV-2)) and the closely related asinine herpes viruses 
4 (AHV-4), asinine herpes viruses 5 (AHV-5) and asinine 
herpes viruses 6 (AHV-6).21, 22 AHV-2 has also been de-
tected by PCR in lung tissue of EMPF affected horses,3, 23 
and AHV-5 has been associated with a case of pyogran-
ulomatous pneumonia in a horse.23 Clinical relevance 
and role in pathogenesis of these viruses is still un-
clear.20, 24 Synergism of different gamma herpesviruses 
in pathogenesis could potentially occur.19, 25 Clinical 
signs of EMPF depend on the stage of disease and in-
clude tachypnoea, increased respiratory effort, tachycar-
dia, weight loss/poor overall condition, intermittent 
fever and cough.12, 26 Inflammatory changes and hypox-
emia can be seen on hematology and biochemistry.26, 27 
Diagnosis is based on distinct changes on thoracic radi-
ographs and ultrasonographic images histologic exam-
ination, as well as detection of EHV-5 in BAL fluid 
(BALF) or lung tissue.12, 26 There is little information on 
treatment of EMPF. Corticosteroid, acyclovir or valacy-
clovir and doxycycline therapy for several weeks are 
described but the long-term prognosis of EMPF remains 
poor.2, 26, 27 A recent case series described short-term sur-
vival as 57% in 14 cases, with only 14% surviving longer 
than 6 months after diagnosis.2 This case series provides 
further information on the association of different gam-
ma herpesviruses with EMPF and highlights the differ-
ent clinical features of EMPF. EMPF has to be kept in 
mind as a differential diagnosis for horses with acute or 
chronic lower respiratory tract disease including equine 
asthma syndrome or bronchopneumonia.
Cases
Case 1
A 23-year-old Irish Warmblood mare was presented in 
June 2017 due to persistent anorexia, weight loss and 
exercise intolerance of three months duration. The re-
Table 1: Summary of published equine multinodular pulmonary fibrosis (EMPF) case reports with PCR diagnosed coinfec-
tion of equine herpesvirus (EHV)-5 and EHV-2 or asinine herpesvirus (AHV)-5 between 2007 – 2019.
Positive PCR lung tissue
Number of cases EHV-5 EHV-2 AHV-5
Williams et al. 200712 24 (23 control) 24 (0 control) 8 (1 control)
Hart et al. 20086 1 1 0
Wong et al. 200826 5 5 0
Belgrave et al. 200947 5 5 0
Poth et al. 20099 5 4 3
Niedermaier et al. 20108 2 2 1
Verryken et al. 201048 1 1 0
Lehmbecker et al. 20117 1 1 1*
Soare et al. 201113 2 2 0
Tomlinson et al. 201115 1 0 0
Back et al. 20123 1 1 0 1
Gomez de Witte et al. 201223 1 0 0 1
Schwarz et al. 201210 1 1 0
Schwarz et al. 20131 5 5 0
Schwarz et al. 201311 1 1 0
Spelta et al. 201314 3 3 0
Dunowska et al. 20145 1 1 0
Easton-Johnes et al. 20192 14 12 0
Total 74 69 13 (18.8%) 2
* only in small amounts on Real-Time PCR detected
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of white, viscous mucus (amount: 2.5/5; color: 3/5; 
apparent viscosity 3.5/5)30 and a thickened carina were 
visualized. Cytological evaluation of a tracheal aspirate 
(TA) was consistent with severe chronic neutrophilic 
lower airway inflammation (Table 2). Bronchoalveolar 
lavage (BAL) confirmed the diagnosis of mild neutro-
philic lower airway inflammation with activated mac-
rophages (Table 2). A panherpes nested PCR of BAL 
secretion with subsequent sequencing of the PCR prod-
uct revealed an inconclusive result due to superimposed 
sequences. Cloning of the PCR product showed the 
presence of EHV-2 as well as AHV-5 (Fig. 2).
Cytological examination of a fine needle aspirate of the 
lung lesions showed presence of mild mixed inflamma-
tion (erythrocytes, neutrophils and macrophages as well 
as a few mast cells, eosinophil granulocytes, mesotheli-
al cells and high prismatic ciliated epithelial cells were 
seen, no bacteria or and no neoplastic cells were found). 
In the examination of the lung biopsy few bronchi, al-
veolar tissue and collagen connective tissue were seen. 
The amount of macrophages in the alveoli was increased 
and they contained several haemosiderophages. Neutro-
phils, lymphocytes and plasma cells were present in 
smaller numbers. A mild suppurative and histiocytic 
pneumonia was diagnosed. A panherpes nested PCR 
performed on lung tissue samples was positive for EHV-
5 (Fig. 2). The diagnosis of EMPF was made. Antiviral 
therapy was started with valacyclovir (Valaciclovir-Me-
pha, Mepha Pharma AG Basel, Switzerland, 30 mg/kg, 
TID, PO for 48 hours, followed by 20 mg/kg TID, PO 
for 28 days). A tapering course of dexamethasone was 
added (Dexadreson ad us. vet., MSD Animal Health 
GmbH Luzern, Switzerland, 0.1 mg/kg SID, PO for 
10 days, 0.05 mg/kg SID, PO for 10 days, 0.05 mg/kg 
q48 h, PO). Penicillin (Penicillin Natrium Streuli ad us. 
vet., Streuli Pharma AG, Uznach, Switzerland, 30’000 
IU/kg QID, IV), gentamicin (Genta-100 ad us. vet., 
CP-Pharma Handelsges. mbH, Burgdorf, Germany, 
9 mg/kg, SID, IV) and flunixin (Flunixine ad us. vet., 
Biokema SA, Crissier, Switzerland, 1.1 mg/kg SID, IV) 
were administered for four days and changed to doxy-
cycline (Doxylin 100% ad us. vet., Raamsdonksveer, 
The Netherlands, 10 mg/kg, BID, PO for 30 days) for 
prevention of complications from the ovarian hemato-
ma. On recheck examination after one month of anti-
viral treatment, the mare was lethargic, showed tachyp-
noea (24 breaths/min) and moderate abdominal effort 
during respiration. On lung auscultation severe in-
creased bronchovesicular sounds, wheezes and friction 
rubs were heard on both sides of the lungs. Hypoxemia 
worsened (from pO2 72 mmHg to 63.3 mmHg) and fi-
brinogen and SAA further increased (from 405.6mg/L 
to 2198.2mg/L). Thoracic radiographs and ultrasound 
were consistent with progressive EMPF pathology. Based 
on the progressive deterioration and poor prognosis, the 
ferring veterinarian palpated an abdominal mass on 
rectal examination two days prior to presentation, which 
was suspected to be a focal impaction. A dental exami-
nation was without abnormal findings and the mare was 
dewormed with ivermectin three months prior to pres-
entation (dose unknown, PO). As the abdominal mass 
persisted despite laxative therapy with mineral oil, the 
mare was referred for further diagnostics and treatment. 
No behavioral changes were reported and the mare was 
bright, alert and responsive. The mare had a thin body 
condition score (3/9), normal rectal temperature 
(37.6 °C) and heart rate (36 beats/min). Respiratory rate 
was slightly elevated (18 breaths/min). There was no 
increased inspiratory effort and the horse showed a nor-
mal costoabdominal respiratory pattern. On lung aus-
cultation, mild to moderate bilateral increased bron-
chovesicular sounds were heard, crackles and wheezes 
were absent. Mild bilateral serous nasal discharge was 
seen but cough was absent. The remainder of the phys-
ical examination was within normal limits. On rectal 
examination the abdominal mass was diagnosed as an 
enlarged right ovary (12 × 10 × 10cm). On rectal ultra-
sonography it measured 10 cm in diameter with a hon-
eycomb structure. The performed hematology and bio-
chemistry analysis showed clinically significant 
abnormalities including hyperfibrinogenemia, hyper-
globulinemia and an elevated SAA (Table 2). A working 
diagnosis of a granulosa thecal cell tumor or ovarian 
hematoma and chronic lower respiratory tract disease 
was made. Diagnostics of the ovarian mass were pursued 
first to rule out neoplastic disease. Thoracic radiographs 
and abdominal paracentesis were performed to evaluate 
the presence of metastatic abdominal or lung disease. 
There were no neoplastic cells evident on cytologic ex-
amination of the abdominal fluid. A generalized severe 
interstitial lung pattern with both a structured nodular 
and an unstructured pattern, was diagnosed (Fig. 1A). 
EMPF or metastatic disease originating from the sus-
pected ovarian tumor were considered as differential 
diagnosis for the radiographic findings. Additional re-
sults became available several days later and included a 
normal Anti-Müller hormone ruling out granulosa cell 
tumor (0.23 ng/mL Ref range <4 ng/mL)28 and normal 
thymidine-kinase concentrations (tumor marker), mak-
ing a tumor unlikely (1.4 U/L Ref range < 2.7 U/L).29 
Cytologic examination of a fine needle aspirate of the 
right ovary mass per rectum was consistent with an ovar-
ian hematoma. Neoplastic disease of the ovaries was 
ruled out and further diagnostics for the respiratory 
disease were pursued. Ultrasonographically, the pulmo-
nary surface was moderately irregular producing comet 
tail artefacts, and multiple subpleural nodules of approx-
imately 2 to 5 cm in diameter were found (Fig. 1B). On 
arterial blood gas analysis, hypoxemia was present (Ta-
ble 2). Performing airway endoscopy, moderate amounts 
Fallberichte | Case reports
248 SAT | ASMV 4 | 2020 Band 162, Heft 4, April 2020, 245–256, © GST | SVS
A case series highlighting 
the role of different 
gamma-herpesviruses 
in Equine Multinodular 
Pulmonary Fibrosis
L. Scheurer et al.
Table 2: Laboratory results of the three equine multinodular pulmonary fibrosis (EMPF) cases.
Case 1 Case 2 Case 3 Reference  
interval
Hematology
PCV (%) 32 28 39 30-42
Hemoglobin (g/dL) 10.9 10 13.6 10.8-14.9
Erythrocytes (103/mL) 6.2 5.89 7.96 6.2-9.0
MCH (pg) 16 17 17 15-18
MCHC (g/dL) 34 36 35 35-37
MCV (fl) 48 47 48 41-50
Leukocytes (106/mL) 5.6 12.6 20.5 4.7-8.2
Thrombocytes (103/mL) 258 188 220 119-250
Neutrophils (103/mL) 4.19 5.71 15.28 3.02-5.78
Segmented neutrophils (103/mL) No data No data 15.28 3.02-5.78
Band neutrophils (103/mL) No data No data 0 0.00-0.08
Basophiles (103/mL) 0.01 0.01 0.21 0.00-0.07
Monocytes (103/mL) 0.16 0.3 0.1 0.00-0.18
Eosinophils (103/mL) 0.45 0.02 No data 0-0.22
Anisocytosis few No data few few
Lymphocytes (103/mL) 0.75 0.98 4.92 1.020-3.47
Chemistry
Fibrinogen (g/L) 7.0** 6 4 1-5 (1.2-2.85**)
Serum amyloid A (mg/L) 405.6 1552.4 No data 0.5-1.2
Total bilirubin (mcmol/L) 30.8 55* 12.8 19-39 (17.4-35.2*)
Glucose (mmol/L) 5.5 4.9 4.7 4.5-5.9
Urea (mmol/L) 4.7 4.6 5.2 3.5-7.0
Creatinine (mcmol/L) 91 102 111 82-147
Protein Biuret (g/L) 60 71 67 57-70
Albumin (g/L) 26 23 26 25-34
Alkaline phosphatase (U/L) 223 289 271 81-183
ASAT (GOT) (U/L) 190 146 227 229-393
GGT (U/L) 13 13 21 6-31
GLDH (U/L) 5.1 3.9 1.1 0.5-2.2
SDH (U/L) 3.6 6.5 3.2 0.1-7.6
CK (U/L) 135 92 502 112-305
LDH (U/L) 702 340 667 369-822
Sodium (mmol/L) 139 138 144 139-147
Potassium (mmol/L) 3.8 3.4 4.3 2.3-4.6
Chloride (mmol/L) 99 97 104 98-106
Calcium (mmol/L) 3.00 2.67 2.81 2.9-3.3
Magnesium (mmol/L) 0.69 0.61 0.68 0.6-0.8
Phosphate (mmol/L) 0.98 1.01 0.87 0.7-1.3
Arterial blood gas
pH 7.45 7.47 7.44 7.35-7.47
pCO2 (mmHg) 38.2 44 44 36-46
HCO3 (mmol/L) 26.7 29 27.9 22-29
Anion Gap (mmol/L) 13.9 11.8 19.9 9-16#
tCO2 (mmol/L) 30.4 29.3 27-33#
BE (mmol/L) 2.5 5.0 3.7 1.1-7.1#
pO2 (mmHg) 72 78 87 80-100
tHb (g/dL) 12.8 11.9 10-18
sO2 (%) 95 97 93-100
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mare was euthanized. Relevant macroscopic findings on 
post mortem examination was the presence of multifo-
cal to coalescing different sized (up to 5 cm in diameter) 
whitish, firm nodules in all lung lobes (Fig. 3). Histolo-
gy findings fulfilled all criteria for a severe multinodular 
pulmonary fibrosis were seen, such as severe fibrosis of 
the parenchyma, large amounts of neutrophils and mac-
rophages in the alveolar spaces, pneumocyte type II 
hyperplasia and some syncytial cells. No intranuclear 
inclusions could be seen. Panherpes nested PCR of lung 
Case 1 Case 2 Case 3 Reference  
interval
Tracheal aspirate
TA neutrophils (%) ++++ No data +++ ((+)) – (+)/32±8.9##
TA macrophages (%) (+) (+) (+)/24±4.0## 
TA eosinophils (%) (+) (-) ((+))/<1.0##
TA tracheobronchial epithelium cells (%) ((+)) ((+)) ((+)) – (+)34±6.6##
Broncho alveolar lavage
BAL cell count (cells/mL) 250 650 688 184±22
BAL neutrophil count (%) 11.0 39 37.3 4.6±1
BAL macrophages (%) 36.5 41 25.4 57.6±4
BAL basophils (%) 0 0 1.4 3.85±0.59
BAL eosinophils (%) 0 0 0 0.29±0.59
BAL lymphocytes (%) 51.5 18.5 35.9 36.0±3
BAL mast cells (%) 1.0% 1.5 0 1.2±0.3#
Serology (Competitive ELISA, Testkit VMRD Inc.)
B. caballi 5% (-) ≤40% negative###
≥40% positive





B. caballi and T. equi (-)
(-) not found, ((+)): rare, (+): few, +: moderate, ++: moderate-lots, +++: lots, ++++: in huge numbers; BAL: bronchoalveolar 
lavage. BAL cell counts are based on 200 cells; * measured stall side with a point of care (POC) analyzer, in the reference 
column * indicates the reference range of the POC analyzer; ** New reference range for the in-house laboratory valid after 
February 8, 2017; # Animal Health Diagnostic Center of Cornell University; ## Derksen et al (1989)49; ### Competitive ELISA 
(Testkit VMRD Inc.), results in % of inhibition.
Figure 1A and B: Lateral radiograph of the caudodorsal lung field (A) of 23-year-old Irish Warmblood (case 1) demonstrates 
a generalized severe unstructured and structured (nodular) interstitial lung pattern. Ultrasound images of the lung (B) in the 
same horse show a heterogeneous subpleural pulmonary nodule (white arrowheads). During real-time imaging, the nodule 
was moving synchronously with respiration.
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tissue was positive for EHV-2 (Fig. 2). On the cranial 
pole of right ovary, a blood-filled cavity of 6 × 4 × 4 cm 
was seen and diagnosed macroscopically and histologi-
cally as a hematoma of the right ovary.
Case 2
A 15-year-old Oldenburg gelding was presented in July 
2013 with a two-week history of recurrent fever (up to 
40 °C), tachypnoea, exercise intolerance and weight loss 
despite a good appetite. The referring veterinarian treat-
ed the horse with broad-spectrum antibiotics (trimeth-
oprim-sulphonamide, dose unknown) and an unknown 
NSAID (dose unknown) with suspicion of viral or bac-
terial infection without improvement. At presentation 
the gelding had a thin body condition score (4/9), an 
elevated rectal temperature (38.6 °C), tachypnoea 
(52 breaths/min) and a normal heart rate (40 beats/
min). Mild abdominal effort and nostril flaring was 
present during respiration, but no dyspnea or cough was 
evident. On lung auscultation increased in- and expir-
atory bronchovesicular sounds on both sides were 
heard, crackles or wheezes were absent. Increased 
sounds on tracheal auscultation were present. Bilateral 
serous nasal discharge and mild depigmentation of both 
nostrils were noticed. The remainder of the physical 
examination was within normal limits. Based on histo-
ry and physical examination, a diagnosis of lower res-
piratory tract disease was made, and further diagnostics 
performed. On arterial blood gas analysis, hypoxemia 
was present. Hematology and biochemistry analysis 
showed leukocytosis, hyperfibrinogenemia, and elevat-
ed SAA (Table 2). Upper and lower airway endoscopy 
were without any abnormal findings. Cytology of BAL 
fluid showed a neutrophilic inflammation with evi-
dence of moderate pulmonary hemorrhage and mildly 
increased amounts of mucus. No bacteria, fungus or 
neoplastic cells were present (Table 2). On thoracic ra-
diographs, a generalized severe bronchointerstitial pat-
tern with a focal ill-defined alveolar pattern dorsal to 
the caudal vena cava and blurred to invisible pulmonary 
vessels and caudal vena cava were seen. Ultrasonograph-
ically, the pulmonary surface was mildly to moderately 
irregular producing comet tail artefacts, and a small 
amount of anechoic free fluid was found. Due to fever 
of unknown origin, treatment was started with penicil-
lin (30’000 IU/kg QID, IV), gentamicin (9 mg/kg, SID, 
IV), metronidazole (pharmaceutical compounding, 
Apotheke Tierspital Zurich, Switzerland, 25 mg/kg 
BID, PO), flunixin (2.2 mg/kg, BID, IV). Over the next 
five days the gelding did not improve clinically, and 
further diagnostics were performed. The horse tested 
negative for blood parasites (Babesia caballi, Theileria 
equi) on PCR and serology (Table 2). A lung biopsy was 
performed and showed mild to moderate interstitial 
lung fibrosis, accompanied by purulent, histiocytic 
pneumonia of unknown origin. No neoplastic cells, 
bacteria or fungi were present. A panherpes nested PCR 
of biopsy material revealed the presence of AHV-5 
(Fig. 2). A diagnosis of EMPF was made, and a guarded 
prognosis given. Antiviral therapy was started with val-
acyclovir (27 mg/kg, TID, PO for 48 hours, followed 
by 18 mg/kg BID, PO). Additionally, the gelding was 
inhaled with salbutamol (Ventolin, GlaxoSmithKline 
AG, Münchenbuchsee, Switzerland, 10 puffs TID) and 
fluticasone (Axotide, GlaxoSmithKline AG, München-
buchsee, Switzerland, 10 puffs TID) to reduce airway 
inflammation and provide relieve from dyspnea. Dex-
amethasone was added (0.05 mg/kg SID, PO). Antibi-
otics were continued to prevent secondary bacterial 
infection and changed to exclusively intravenous ad-
ministration with penicillin (30’000 IU/kg QID, IV) 
and marbofloxacin (Forcyl ad us. vet., Vetoquinol AG, 
Bern, Switzerland, 2 mg/kg, BID, IV). As the horse 
remained febrile, flunixin (1.1 mg/kg SID, IV) was con-
tinued. During the next 15 days fever spikes of up to 
40 °C occurred. Coughing, severe tachypnoea, dyspnea 
and anorexia developed. Radiographic and ultrasono-
graphic findings were stationary to mildly worsened. 
Due to the progressive deterioration and poor progno-
sis the gelding was euthanized three weeks after the 
initial presentation. Relevant macroscopic findings on 
post mortem examination was a severe increased con-
sistency of all lung lobes with bad retraction of the lung 
and a nodular pattern. Histologically a severe multifo-
cal to coalescing fibrosing, histiocytic and suppurative 
bronchointerstitial pneumonia with rare viral intranu-
clear inclusion bodies was present. To quantify the 
collagen fibers in the lung, a Van Gieson special stain 
was applied, and an increase of collagen fibers was vis-
Figure 2: Phylogenetic tree of equid herpesviruses including sequences from the three 
equine multinodular pulmonary fibrosis (EMPF) cases (black symbols). References were 
downloaded from NCBI Genbank, where available. The maximum likelihood tree is based 
on a MUSCLE alignment of 158-170nt long fragments (panherpes nested PCR product) 
of the polymerase coding region and was tested with 1000 bootstraps. For several equid 
herpesviruses, such as EHV-6/AHV-1, EHV-9, AHV-6 no references were available that cov-
ered the whole fragment length. BAL: Isolated from bronchoalveolar lavage fluid (BALF); 
lung: isolated from lung tissue obtained during post mortem examination; biopsy: isolat-
ed from lung tissue obtained by lung biopsy.
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ualized. The panherpes nested PCR of lung tissue con-
firmed the presence of AHV-5 (Fig. 2).
Case 3
A 15-year-old, Belgium Warmblood mare was presented 
in November 2012 due to progressive coughing and na-
sal discharge of two years duration. The referring veter-
inarian diagnosed the horse with severe equine asthma 
six months prior to presentation. Treatment consisted 
of several courses of acetylcysteine (ACC) with or with-
out clenbuterol (both doses unknown, PO) and two 
courses of prednisolone (unknown dose and duration, 
PO). Management changes consisted of feed change to 
silage and grass, bedding change from straw to wood 
shavings. Show jumping was discontinued and the mare 
used for pleasure riding only. The clinical signs were 
unresponsive to treatment and the mare was referred for 
further diagnostic procedures and therapy. There was 
no fever reported. On admission, the mare had a normal 
body condition score (5/9), rectal temperature (37.7 °C), 
heart rate (40 beats/min) and respiratory rate (16 breaths/
min). Mild abdominal effort was present during respi-
ration, but no dyspnea was evident. During a rebreath-
ing test, increased bronchovesicular sounds were auscul-
tated but crackles and wheezes were absent. Rattles were 
present on tracheal auscultation. Bilateral serous nasal 
discharge and mild depigmentation of both nostrils were 
noticed. The remainder of the physical examination was 
within normal limits. Based on history and physical 
examination, a presumptive diagnosis of chronic lower 
respiratory tract disease was made, and further diagnos-
tics were performed. Hypoxemia on arterial blood gas 
analysis (Table 2) and prolonged recovery time after 
lunging were indicative of ventilation/perfusion mis-
match. On hematology and biochemistry analysis, sig-
nificant abnormalities included leukocytosis with left 
shift and lymphocytosis (Table 2). On airway endosco-
py moderate amounts of white, viscous mucus and a 
thickened carina were visualized (amount: 2/5; color: 
3/5; apparent viscosity 3/5).30 Cytological evaluation of 
a tracheal aspirate (TA) and BAL (Table 2) were consist-
ent with equine asthma (Table 2). A diagnosis of severe 
equine asthma was made, and treatment started with 
prednisolone (Prednisolon Vétoquinol ad us. vet., 
Vetoquinol AG, Bern, Switzerland, 2 mg/kg, 1.5 mg/kg, 
1 mg/kg SID, PO, for 10 days each) and ACC (Acetyl-
cystein ad us. vet., Dr. G Bichsel AG, Unterseen, Swit-
zerland, 5 mg/kg BID, PO) and further management 
changes to ensure a dust and hay free environment were 
recommended. At recheck examination six weeks later, 
the clinical signs did not improve and laboratory and 
endoscopy findings as well as cytological evaluation of 
TA and BAL were unchanged. On thoracic radiographs, 
a generalized severe interstitial to miliary lung pattern 
with peribronchial cuffing and blurring of the pulmo-
nary vessels and the caudal vena cava was seen. Ultra-
sonographically, the pulmonary surface was moderately 
irregular producing comet tail artefacts, and multiple 
small subpleural nodules (2-3mm in diameter) were 
found. Imaging findings were consistent with EMPF, 
Figure 3A and B: Gross post mortem (A) and histologic lesions (B) of a 23-year-old Irish Warmblood (case 1) with equine 
multinodular pulmonary fibrosis (EMPF). Note the large discrete nodules of fibrosis with sharp borders (arrows) adjacent to 
grossly normal lung tissue (A). Note the thickened parenchyma due to severe interstitial fibrosis (asterisks) and less affect-
ed lung areas where only few aerated alveolar spaces (arrows) are still visible (B, magnification 4x), Hematoxylin-Eosin (HE) 
staining. Inset: Arrow: Intranuclear inclusion body (D, magnification 40x), HE staining.
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granulomatous pneumonia or neoplasia. A sample of 
BAL fluid was submitted for panherpes nested PCR 
which was negative. A lung biopsy was performed and 
showed multifocal interstitial lung fibrosis accompanied 
by a chronic non-purulent pneumonia. No neoplastic 
cells were present. The diagnosis of EMPF was made and 
a guarded prognosis given. Palliative treatment was start-
ed with clenbuterol (Ventipulmin, Boehringer Ingel-
heim GmbH, Basel, Switzerland, 0.8 mcgr/kg BID, PO) 
and dembrexine (Sputolysin, ad us. vet., Boehringer 
Ingelheim GmbH, Basel, Switzerland, 0.3 mg/kg BID, 
PO) and a tapering course of prednisolone (2 mg/kg, 
1.5 mg/kg, 1 mg/kg SID, PO for 10 days each). As the 
mare developed sweating and discomfort which were 
attributed to side effects from clenbuterol, therapy with 
clenbuterol was stopped and dembrexine was changed 
to ACC (5 mg/kg BID, PO) due to convenience. Over 
the following next months, clinical and laboratory 
 findings were unchanged on recheck examination. Ther-
apy was changed to inhalation therapy (fluticasone 
2 mcgr/kg BID) and a repeated course of tapering oral 
prednisolone was attempted. Initially the owner report-
ed improvement of clinical signs, however the mare 
worsened when corticosteroid therapy was discontinued. 
On recheck examination eight months after the initial 
presentation, clinical signs and hypoxemia had wors-
ened (pO2: 75 mmHg) and more pathologic lesions were 
seen on thoracic ultrasound. Based on the deteriorating 
condition a poor prognosis was given and no further 
treatment attempted. The mare deteriorated further at 
home, respiratory signs worsened she became anorexic 
and unwilling to move. Based on the progressive dete-
rioration, the mare was euthanized nine months after 
the initial presentation. Relevant macroscopic findings 
on post-mortem examination were an increased consist-
ency of the lung parenchyma and nodular changes most-
ly in both diaphragmatic lung lobes. Histological exam-
ination revealed a severe multifocal to diffuse chronic 
granulomatous pneumonia and multifocal interstitial 
fibrosis, as well as a diffuse fibrosis of the pleura as con-
firmed by the Van Gieson special stain for collagen fib-
ers. Panherpes nested PCR was performed from lung 
tissue and showed the presence of AHV-5 (Fig. 2). 
Discussion 
This case series provides further information about the 
association of different gamma herpesviruses with 
EMPF and highlights the different clinical features of 
EMPF. EMPF has to be kept in mind as a differential 
diagnosis for horses with acute or chronic lower respira-
tory tract disease including equine asthma syndrome or 
bronchopneumonia. Antiviral treatment with valacy-
clovir in two of three horses in conjunction with sup-
portive therapy did not result in improvement. Remark-
able in this case series was the detection of AHV-5 in 
absence of EHV-5 in two of the cases. Coinfections 
cannot be excluded completely as the panherpes nested 
PCR detects only the dominant virus.
Gammaherpesvirinae, which include EHV-2, EHV-5, 
EHV-7 (also called AHV-2) and the closely related asi-
nine herpes viruses AHV-4, AHV-5 and AHV-621, 22 may 
have a role in pulmonary fibrosis as evidenced by exper-
imental murine γ-herpesvirus 68 (MHV68) models, as 
well as humans with idiopathic pulmonary fibrosis cor-
related with Epstein-Barr Virus (EBV) infection.17, 18, 31 
AHV-4, AHV-5 and AHV-6 have been detected in don-
keys with interstitial pneumonia, with lesions similar to 
EMPF.22, 32 Detection of AHV-5 in horses is rarely de-
scribed. AHV-5 was detected in horses with respiratory 
disorders or “poor performance syndrome”.24 Concur-
rent detection of EHV-5 and AHV-5 in an EMPF case 
has been described in a case report.3 AHV-5 has also 
been detected in lung tissue of a horse with pyogranu-
lomatous pneumonia, a pathology differing from de-
scribed EMPF cases in horses and interstitial pneumonia 
in donkeys with AHV-5 infection.23
Detection technique and virus load may be responsible 
for the inconsistent results from BALF, lung biopsy and 
necropsy in two of the cases. A similar finding was re-
ported in a recent case series, where one horse tested 
negative for EHV-5 on qPCR of lung tissue ante-mortem 
but proved to be positive for EHV-5 post-mortem.2 Two 
other horses were negative on testing of lung tissue for 
EHV-5 despite characteristic histopathological lesions2. 
Similarly one horse with hypertrophic osteopathy sec-
ondary to nodular pulmonary fibrosis also tested nega-
tive for EHV-5 on post mortem lung examination.15 In 
our case series, EHV-5 was detected only in one case in 
lung tissue ante- mortem. The other two cases were test-
ed positive for AHV-5 in lung tissue post-mortem.
Panherpes Nested PCR is a sensitive technique to iden-
tify a broad range of herpesviruses. This method targets 
a highly conserved region of the herpesviral DNA pol-
ymerase gene. Using degenerate consensus primers, PCR 
is able to not only detect known herpes viruses, but also 
novel herpesviruses without information on DNA se-
quence.33 Sequencing of PCR products is impaired if the 
viral load is very low. Incomplete reads and incorrect 
incorporation of bases by Taq DNA polymerase may 
occur.33 Co-infections may often be overlooked as pri-
marily the sequence of the dominant virus will be iden-
tified in a panherpesvirus PCR. Superimposed sequenc-
es and double peaks in electropherograms are indications 
for co-infections. However, only subsequent cloning 
allows separation of the sequences and hence determi-
nation of the individual viruses. In case 1, three differ-
ent equid gamma herpesviruses were detected. If this 
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reflects different virus localization/excretion patterns 
(BAL versus lung tissue) or serial circulation of the vi-
ruses cannot be conclusively answered. Induction of 
fibrosis occurs during latency of the virus in the lungs. 
In this phase, low virus DNA copy numbers beyond 
detection limits of the assay may be present.34 Viral load 
in BALF may have been reduced in some of our cases 
due to prior medication, which has also been shown in 
another study.26 On the other hand, administration of 
steroids may reactivate latently present gamma herpes-
viruses that are not causally involved in the generation 
of EMPF, such as EHV-2. If and how the reactivation of 
these viruses may influence the clinical outcome is un-
clear. 
Gamma herpesviruses are suspected to be involved in 
pulmonary fibrosis in humans, rodents, and domestic 
animals (dog, cat, horse).35, 36 There are similarities be-
tween fibrotic disease in these species and EMPF in 
horses regarding the age at clinical onset and progression 
of the disease as well as poor response to therapy.25 No 
etiologic cause for fibrosis has been found in cats and 
dogs. In horses, donkeys and humans, pulmonary fibro-
sis was associated with EHV-5, AHV-4/5 and different 
gamma herpesviruses respectively.37 Epstein-Barr Virus 
(EBV), cytomegalovirus, human herpesvirus (HHV) -7 
and -8 were found in patients with idiopathic pulmonary 
fibrosis (IPF) in nearly 100% of diseased lungs compared 
with 40% of healthy patients.38 Virus factors (latent ver-
sus lytic infection, expressed viral genes and chemok-
ines), lung immunology (pre-existing TH2 environ-
ment, aged immune response), host factors (natural 
versus aberrant host, aged lung) and additional injury 
(co-infections, toxic injury) influence the development 
of pulmonary fibrosis.25 Trigger factors of fibrosis are 
poorly understood. Epithelial cell injury, abnormal fi-
broproliferation, inflammation, deposition of extracel-
lular matrix substances and viruses as co-factors for 
initiation, promoting or exacerbating pulmonary fibro-
sis are described.39, 40 Although recovery from severe 
pulmonary damage was recently demonstrated in an 
equine model of perilla mint ketone-induced acute lung 
injury,41 fibrosis is still characterized as a chronic, pro-
gressive, irreversible pathologic process with poor prog-
nosis.41 
Pathophysiology of EMPF is largely unknown. A recent 
study showed that epithelial cells lining the mucosa of 
nasal and tracheal explants and primary equine respira-
tory epithelial cells were not susceptible to EHV-5 in-
fection. In contrast, EHV-5-positive cell clusters were 
observed after infection of lung explants with EHV-5.20 
In the same study 10% of the inoculated T and B lym-
phocytes synthesized intracellular virus antigen post 
infection, indicating spreading the of the virus via cell-
to-cell transfer.20 The authors concluded based on their 
results that a hypothetical model of EHV5 pathogenesis 
in horses starts with transportation of virions by the 
mucociliary escalator towards the tonsillar crypts in the 
nasopharynx. EHV-5 then directly infects lymphocytes 
situated in the lymphoid follicles. From there the infect-
ed lymphocytes reach the blood stream directly or via 
lymph vessels and draining lymph nodes. The virus 
spreads by cell to cell transfer to adjacent lymphocytes 
in the lymphoid follicles or draining lymph nodes. EHV-
5 infected lymphocytes might either undergo apoptosis 
or survive and provide a life-long reservoir for EHV-5. 
Via blood flow or via lymphocyte-homing, EHV-5 in-
fected lymphocytes (re)routes to different parts of the 
respiratory tract, e.g. nasal cavities, trachea or lungs. 
Amplification of the infection in epithelial cells, shed-
ding of high viral loads in respiratory secretions and 
cell-cell transfer to neighboring alveolar cells may ensue. 
The onset of fibrosis may be triggered by viral replica-
tion and host-specific predisposing factors.20 
Acyclovir acts as a nucleoside analog that substitutes 
guanosine triphosphate in DNA synthesis. Due to its 
mode of action, the antiviral effect occurs only during 
replication of the virus. It is selectively toxic to herpes-
viruses due to its higher affinity for viral thymidine 
kinase (TK) and DNA polymerase compared with host 
TK and cellular polymerase.42 Early treatment of neu-
ropathogenic EHV-1 infection in horses with valacyclo-
vir has shown decreased viral replication, viral shedding 
and viremia43. Similar action is supposed to occur in 
horses with EHV-5 infection. Acyclovir is less effective 
against equine herpesviruses than against human herpes 
viruses such as herpes simplex virus and has a poor oral 
bioavailability in horses. Valacyclovir, the prodrug of 
acyclovir, shows better oral bioavailability data.44 Still, 
the best studied antiherpetic drug for EHVs due to its 
lower costs, high safety and availability remains acyclo-
vir.45 Based on pharmacokinetics and empiric values, 
various therapeutic protocols with valacyclovir are de-
scribed. A loading-dose regime of 27 mg/kg orally every 
eight hours for the first two days followed by a mainte-
nance dose regimen of 18 mg/kg orally every 12 hours 
can be used as a guideline.44 In the presented case series, 
antiviral therapy was not effective but successful treat-
ment with valacyclovir has been reported in a horse in 
the past.11 A recent study has shown no short-term effect 
of valacyclovir on EHV-5 viral load in EMPF affected 
horses.45 No association between EHV-5 viral load in 
the lungs ante mortem and survival time was found in 
14 cases.2 Treatment with antivirals in 7/14 horses 
(6 with valacyclovir, 1 with acyclovir) was also not as-
sociated with short-time survival.2 This is not surprising, 
as fibrosis is induced during the latency of the virus, not 
during the active replicating phase when valacyclovir 
exerts its effect. The long-term effect of antivirals, how-
ever is unknown and needs to be investigated. Corticos-
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teroids have also been proposed as treatment for EMPF 
and short-term mortality was reduced in 8/14 horses 
treated with corticosteroids compared to six horses with-
out corticosteroid therapy.2 
Clinical signs and findings in BALF and TA cytology 
can be similar to common chronic respiratory diseases, 
especially equine asthma syndrome (recurrent airway 
obstruction (RAO), inflammatory airway disease (IAD), 
chronic obstructive bronchitis (COB).46 In some cases 
pyrexia, weight loss, tachypnea and severe dyspnea are 
present which can help distinguish equine asthma syn-
drome from EMPF.26 On blood analysis, a marked in-
flammatory response with neutrophilia and hyperfibrin-
ogenemia is common in cases with EMPF.12 Radiographs 
show an interstitial to nodular pulmonary pattern.26 
BALF and TA cytology and culture is helpful to rule out 
fungal, bacterial, and silicate-induced granulomatous 
interstitial lung disease but it is often not possible to 
distinguish equine asthma syndrome from acute EMPF. 
BALF can be submitted for PCR and many reported 
EMPF cases were positive for EHV-5; however a negative 
result does not fully rule out EMPF.27 Thoracic radio-
graphs and ultrasound are helpful in distinguishing 
equine asthma from EMPF. Lung biopsies allows a defi-
nite ante mortem diagnosis. Histologically, multiple, 
well-demarcated nodular regions of pulmonary intersti-
tial fibrosis with mixed inflammatory cell infiltration 
and a positive EHV-5 PCR result are reported as gold 
standard.26 Overall, prognosis for EMPF remains poor. 
In the recent case series of 14 horses the median short- 
and long-time survival were 18 and 27.5 days, respec-
tively2 with only one horse being alive more than three 
years after initial diagnosis. These findings are compa-
rable to the outcome of the three horses in the present-
ed case series. One horse survived nine months after 
initial diagnosis, the other two cases were euthanized 
after 23 days and 45 days, respectively. Severity of tho-
racic radiographic changes and EHV-5 viral load meas-
ured by quantitative qPCR in lung tissue at presentation 
did not correlate with survival time. The administration 
of corticosteroids had a positive effect on short-term 
survival.2
In conclusion, EMPF should be considered as a differ-
ential diagnosis for acute or chronic lower respiratory 
disease. Thoracic radiographs and thoracic ultrasound 
should be performed in cases with suspected equine 
asthma syndrome that do not improve with adequate 
therapy. A lack of EHV-5 in BAL fluid or on PCR from 
lung biopsy samples does not rule out EMPF. Other 
equid gamma herpesviruses like AHV-5 should be con-
sidered when investigating the cause of EMPF. If results 
from EHV-5 specific PCR of BAL fluid or lung tissue 
are negative, a panherpes nested PCR (detection of all 
known herpesviruses) with subsequent sequencing to 
determine other potentially involved herpesviruses 
should be pursued.
Fibrose pulmonaire multinodulaire 
équine: une série de cas mettant en 
évidence diverses manifestations  
cliniques
Cette série de cas décrit trois cas de fibrose pulmonaire 
multinodulaire équine (EMPF) diagnostiqués à la Cli-
nique de médecine interne équine de l’Université de 
Zurich entre 2012 et 2017. Des informations actuelles 
sur l’étiologie et les options de traitement sont présen-
tées. Deux chevaux présentaient de légers signes de ma-
ladie chronique des voies respiratoires inférieures et un 
cheval présentait des signes aigus de maladie, notam-
ment des pics de fièvre récurrents et une tachypnée. Le 
diagnostic a été obtenu grâce à un examen physique, des 
résultats radiographiques et des tests PCR pour les virus 
herpès équins (EHV) du liquide de lavage broncho-al-
véolaire (BAL) ou du tissu pulmonaire obtenus par biop-
sie. Tous les chevaux ont été euthanasiés en raison d’une 
détérioration continue après une tentative de traitement. 
L’examen histologique post mortem du tissu pulmonaire 
a montré une fibrose multifocale diffuse à confluente 
sévère dans deux cas et chez un cheval un type de fibrose 
nodulaire discret. La PCR par Panherpes a révélé la pré-
Una serie di casi che illustrano il  
ruolo dei diversi Herpesvirus gamma 
nella fibrosi polmonare multinodulare 
equina 
In questo studio sono illustrati tre casi di fibrosi polmo-
nare multinodulare equina (EMPF) diagnosticati tra il 
2012 e il 2017 presso la clinica di medicina interna equi-
na dell’Università di Zurigo. Le informazioni attuali 
sull’eziologia e sulle possibilità di trattamento sono 
descritte. Due cavalli mostravano lievi segni di una ma-
lattia cronica delle basse vie respiratorie e un cavallo 
aveva dei segni acuti della malattia tra cui picchi ricor-
renti di febbre e tachipnea. La diagnosi è stata determi-
nata via un esame fisico, i risultati radiografici e un test 
PCR per gli herpesvirus equini (EHV) del liquido di 
lavaggio broncoalveolare (BAL) o del tessuto polmona-
re ottenuto mediante biopsia. Tutti i cavalli sono stati 
eutanasiati a causa del continuo deterioramento del loro 
stato dopo il tentativo di trattamento. L’esame istologi-
co post mortem del tessuto polmonare ha evidenziato 
in due casi una grave fibrosi multifocale diffusa o a 
confluenza e in un caso un discreto modello di fibrosi. 
La pan-herpes nested PCR ha rilevato la presenza 
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sence d’ADN de virus herpès équin 5 (EHV-5) dans le 
tissu pulmonaire d›un cheval alors que chez deux autres 
chevaux, le virus de l›herpès asinien 5 (AHV-5) a été 
détecté. L’EMPF doit être considéré comme un diagnos-
tic différentiel chez les chevaux souffrant d’une maladie 
respiratoire aiguë et chronique, y compris les chevaux 
ne répondant pas au traitement de l’asthme équin.
Mots-clés: virus herpès asinien 5; l’virus herpès équin 5; 
cheval; pneumonie interstitielle; fibrose pulmonaire
dell’herpesvirus equino 5 (EHV-5) DNA nel tessuto 
polmonare in un cavallo mentre negli altri due ha rile-
vato il virus dell’herpes asinino 5 (AHV-5). La EMPF 
deve essere quindi presa in considerazione per la dia-
gnosi differenziata nei cavalli che soffrono di una ma-
lattia acuta e cronica delle vie respiratorie compresi i casi 
di cavalli che non rispondono ad un trattamento per 
l’asma equina. 
Parole chiave: virus dell’herpes asinino 5; herpesvirus  
equino 5; cavalli; polmonite interstiziale; fibrosi polmonare
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